X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (55406) 55406
Book Review (11142) 11142
Publication (4250) 4250
Book Chapter (233) 233
Newsletter (134) 134
Book / eBook (106) 106
Conference Proceeding (101) 101
Dissertation (68) 68
Newspaper Article (65) 65
Magazine Article (14) 14
Data Set (8) 8
Trade Publication Article (4) 4
Paper (3) 3
Presentation (3) 3
Web Resource (3) 3
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (45153) 45153
humans (40209) 40209
cancer (18108) 18108
oncology (17816) 17816
male (17218) 17218
female (16792) 16792
hepatocellular-carcinoma (14171) 14171
hepatocellular carcinoma (13757) 13757
animals (13496) 13496
middle aged (12402) 12402
apoptosis (10435) 10435
cell line, tumor (10176) 10176
liver cancer (10018) 10018
aged (9661) 9661
adult (8413) 8413
carcinoma, hepatocellular - drug therapy (8302) 8302
liver neoplasms - drug therapy (8205) 8205
liver neoplasms - pathology (8187) 8187
expression (8181) 8181
carcinoma, hepatocellular - pathology (7871) 7871
tumors (7811) 7811
metastasis (7598) 7598
mice (7585) 7585
gastroenterology & hepatology (7564) 7564
care and treatment (7042) 7042
health aspects (6530) 6530
prognosis (6481) 6481
analysis (6461) 6461
carcinoma (6425) 6425
chemotherapy (6408) 6408
hepatoma (6272) 6272
research (6199) 6199
liver (6078) 6078
proteins (6047) 6047
gene expression (6046) 6046
treatment outcome (5305) 5305
cell biology (5019) 5019
development and progression (4843) 4843
therapy (4839) 4839
pharmacology & pharmacy (4715) 4715
genetic aspects (4517) 4517
cancer therapies (4407) 4407
survival (4387) 4387
apoptosis - drug effects (4376) 4376
carcinoma, hepatocellular - metabolism (4269) 4269
biochemistry & molecular biology (4190) 4190
liver neoplasms - metabolism (4179) 4179
antineoplastic agents - pharmacology (4012) 4012
cell proliferation (3888) 3888
kinases (3865) 3865
cell proliferation - drug effects (3858) 3858
breast-cancer (3835) 3835
medical prognosis (3811) 3811
surgery (3805) 3805
medicine & public health (3746) 3746
signal transduction (3731) 3731
risk factors (3699) 3699
growth (3608) 3608
antineoplastic agents - therapeutic use (3596) 3596
medicine (3595) 3595
medicine, research & experimental (3584) 3584
gene expression regulation, neoplastic (3552) 3552
liver neoplasms - therapy (3547) 3547
studies (3386) 3386
research article (3366) 3366
cell cycle (3338) 3338
carcinoma, hepatocellular - therapy (3315) 3315
hepatitis (3252) 3252
aged, 80 and over (3180) 3180
angiogenesis (3170) 3170
cells (3134) 3134
patients (3094) 3094
carcinoma, hepatocellular - genetics (3081) 3081
liver neoplasms - genetics (3077) 3077
proliferation (3034) 3034
digestive system diseases (3027) 3027
activation (3023) 3023
cirrhosis (3011) 3011
cell growth (2987) 2987
article (2933) 2933
multidisciplinary sciences (2925) 2925
mice, nude (2879) 2879
retrospective studies (2823) 2823
immunohistochemistry (2801) 2801
in-vitro (2773) 2773
drug therapy (2766) 2766
sorafenib (2650) 2650
inhibition (2640) 2640
breast cancer (2638) 2638
down-regulation (2564) 2564
medical research (2520) 2520
biomarkers (2486) 2486
metastases (2449) 2449
abridged index medicus (2447) 2447
disease progression (2386) 2386
hep g2 cells (2377) 2377
cancer research (2374) 2374
antiviral agents - therapeutic use (2373) 2373
xenograft model antitumor assays (2346) 2346
review (2309) 2309
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (62) 62
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (12) 12
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
St. Michael's Hospital - Stacks (3) 3
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reference (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Markham Stouffville Hospital - Stacks (2) 2
St Josephs Health Centre - Stacks (2) 2
Credit Valley Hospital - Special Collections (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Markham Stouffville Hospital - Storage (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Trillium Health Centre - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (54268) 54268
Japanese (667) 667
Chinese (294) 294
French (186) 186
German (183) 183
Korean (81) 81
Spanish (60) 60
Russian (59) 59
Italian (30) 30
Hungarian (29) 29
Polish (24) 24
Portuguese (12) 12
Danish (7) 7
Czech (6) 6
Dutch (4) 4
Finnish (3) 3
Swedish (3) 3
Bulgarian (2) 2
Croatian (2) 2
Romanian (2) 2
Serbian (2) 2
Turkish (2) 2
Arabic (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2492 - 2502
Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to... 
Internal Medicine | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | IMMUNOTHERAPY | SORAFENIB | BLOCKADE | DOCETAXEL | PD-1 | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Liver Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Tumor Burden | Dose-Response Relationship, Drug | B7-H1 Antigen - metabolism | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Nivolumab | Carcinoma, Hepatocellular - pathology | Biomarkers, Tumor - metabolism | Female | Liver Neoplasms - pathology | Aged | Virus diseases | Medical colleges | Care and treatment | Cell death | College teachers | Hepatoma | Comparative analysis | Drug approval | Slopes | Therapy | Pemphigoid | Intravenous administration | Inhibitor drugs | PD-1 protein | Funding | Liver | Medical services | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Infections | Metastasis | Dosage | Cancer therapies | B7 antigen | Acceptability | Incidence | Hepatitis | Liver cancer | Pathways | Quality | Immunotherapy | Safety engineering | Safety management | Safety | Expansion | Drug dosages | Liver diseases | Effectiveness | Mortality | Group dynamics | Patients | Hospitals | Inhibitors | Immune checkpoint | Adults | Solid tumors | Hepatitis C virus | Hepatitis C | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 859 - 870
Journal Article
by Vilgrain, Valérie and Pereira, Helena and Assenat, Eric and Guiu, Boris and Ilonca, Alina Diana and Ilonca, Alina D and Pageaux, Georges-Philippe and Sibert, Annie and Bouattour, Mohamed and Lebtahi, Rachida and Allaham, Wassim and Barraud, Hélène and Laurent, Valérie and Mathias, Elodie and Bronowicki, Jean-Pierre and Tasu, Jean-Pierre and Perdrisot, Rémy and Silvain, Christine and Gerolami, René and Mundler, Olivier and Seitz, Jean-Francois and Vidal, Vincent and Aubé, Christophe and Oberti, Frédéric and Couturier, Olivier and Brenot-Rossi, Isabelle and Raoul, Jean-Luc and Sarran, Anthony and Costentin, Charlotte and Itti, Emmanuel and Luciani, Alain and Adam, René and Lewin, Maïté and Samuel, Didier and Ronot, Maxime and Dinut, Aurelia and Castera, Laurent and Chatellier, Gilles and Delhom - Christol, Elisabeth and Lonjon, Julie and Abdel-Rehim, Mohamed and Dieudonné, Arnaud and Bazin, Christophe and Chagneau-Derrode, Carine and Borentain, Patrick and Bouvier, Antoine and Vervueren, Laurent and Chalaye, Julia and Kobeiter, Hicham and Edeline, Julien and Garin, Etienne and Rolland, Yan and Archambeaud, Isabelle and Eugene, Thomas and Frampas, Eric and Cassinotto, Christophe and Guyot, Martine and Hiriart, Jean-Baptiste and Lapuyade, Bruno and Vergniol, Julien and Bachellier, Philippe and Detour, Julien and Duclos, Bernard and Greget, Michel and Habersetzer, Francois and Imperiale, Alessio and Merle, Philippe and Rode, Agnès and Morvan, Julie and Nguyen-Khac, Eric and Yzet, Thierry and Baudin, Guillaume and Chevallier, Patrick and Mahamat, Abakar and Piche, Thierry and Razzouk, Micheline and Hillon, Patrick and Loffroy, Romaric and Toubeau, Michel and Vincent, Julie and Barabino, Gabriele and Bouarioua, Nadia and Cuilleron, Muriel and Ecochard, Marie and Prevot-Bitot, Nathalie and Leroy, Vincent and Roux, Julie and Sengel, Christian and Bourcier, Valérie and Ganne-Carrie, Nathalie and Seror, Olivier and Costo, Sylvie and Dao, Thông and Pelage, Jean-Pierre and Dumortier, Jérôme and Giammarile, Francesco and Valette, Pierre-Jean and Ghazzar, Nadia and Pellerin, Olivier and Taieb, Julien and ... and SARAH Trial Grp and SARAH Trial Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1624 - 1636
Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of... 
SURVIVAL | THERAPY | ONCOLOGY | COMPETING RISK | TRANSARTERIAL CHEMOEMBOLIZATION | RADIOEMBOLIZATION | QUALITY-OF-LIFE | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Microspheres | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Neoplasm Invasiveness - pathology | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Yttrium Radioisotopes - therapeutic use | Radiotherapy Dosage | Drug Administration Schedule | Administration, Oral | Brachytherapy - methods | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Carcinoma, Hepatocellular - radiotherapy | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Liver Neoplasms - radiotherapy | Sorafenib | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging | Rare earth metals | Antimitotic agents | Product development | Hepatoma | Comparative analysis | Radiotherapy | Antineoplastic agents | Index Medicus | Life Sciences | Liver Neoplasms/drug therapy | Phenylurea Compounds/administration & dosage | Yttrium Radioisotopes/therapeutic use | Niacinamide/analogs & derivatives | Carcinoma, Hepatocellular/radiotherapy | Carcinoma, Hepatocellular/drug therapy | Cancer
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 378 - 390
Journal Article